El mantenimiento a largo plazo es importante1-3

 

La obesidad es reconocida por organizaciones de la salud como una enfermedad crónica, incluyendo la Federación Mundial de la Obesidad y la Asociación Europea para el estudio de la Obesidad.1-5

La obesidad está asociada con más de 195 complicaciones6

 

Las enfermedades cardiovasculares (ECV) son la causa principal de muertes en personas con obesidad.7

40% de los diagnósticos de cáncer en Estados Unidos están asociados con sobrepeso y obesidad.8

Mantener el peso trae beneficios para la salud9-14

 

Perder del 5% de peso o más reduce el riesgo de diabetes9tipo 2, mejora la apnea del sueño10-12, el dolor osteoartrítico12 y el riesgo cardiovascular incluyendo presión arterial y lípidos en la sangre.13,14

Saxenda® es el único agonista del receptor GLP-1 aprobado por COFEPRIS para el control crónico del peso19

 

Aprenda sobre el mecanismo de acción de Saxenda® en sólo 1 minuto

1.- Bray GA, Kim KK, Wilding JPH; on behalf of the World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-723.

2.- Allison DB, Downey M, Atkinson RL, et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring). 2008;16(6):1161-1177.

3.- Frühbeck G, Sbraccia P, Nisoli E, et al. 2015 Milan Declaration: a call to action on obesity - an EASO position statement on the occasion of the 2015 EXPO. Obes Facts. 2016;9(4):296-298.

4.The American Medical Association (AMA) 2013.

5.The World Health Organization (WHO).

6.- Yuen M, Earle R, Kdambi N, et al. A systematic review and evaluation of current evidence reveals 195 obesity-associated disorders (OBAD). Abstract presented at: Obesity Week, November 2, 2016; New Orleans, Louisana. Abstract T-P-3166.

7.- GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13-17. doi:10.1056/NEJMoa1614362.

8.- Steele CB, Thomas CC, Henley SJ et al. Vital Signs: Trends in Incidence of Cancerrs Associated with Overweight and Obesity -United States, 2005-2014. Morb Mortal Wkly Rep. 2017;66(39):1052-1058.

9.- Knowler WC, Barrett-Connor E, Fowler SE, et al. for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle interventio n or metformin. N Engl J Med. 2002;346(6):393-403.

10.- Tuomilehto H Seppa J, Uusitupa M, et al. The impact of weight reduction in prevention ofb the progression of obstructive sleep apnea: an explanatory analysis of a 5-year observational follow up trial. Sleep Med. 2014;15(3):329-335.

11.- Foster GD Borradaile KE Sanders MH, et al. for the Sleep AHEAD Research Group of the Look AHEAD Research Group. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD Study. Arch Intern Med. 2009;69(17):1619-1626

12.- Riddle DL, Stratford PW. Body weight changes and corresponding changes in pain and function in persons with symptomatic knee osteoarthritis: a cohort study. Arthritis Care Res. 2013;65(1):15-22

13.- Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovasculas risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care, 2011;34(7):1481-1486

14.- Datillo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins; a meta analysis. Am J Clin Nutr. 1192;56(2)320-328

15.- Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. Clin Sci (Lond). 2013;124(4):231-241.

16.- Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604.

17.- Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes (Lond). 2010;34(suppl 1):S47-S55.

18.- Schwartz A, Doucet E. Relative changes in resting energy expenditure dur ing weight loss: a systematic review. Obes Rev. 2010;11(7):531-547.

19.- Saxenda®, Información para Prescribir, 16.08.2018 (183300415U0042).

20.- Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol. 1996;31(7):665-670.

21.- Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473-4488.